Posted by Michael Wonder on 27 Jul 2022
Duvelisib for patients with chronic lymphocytic leukaemia
27 July 2022 - NICE has published a final technology appraisal for duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia after two or more treatments.
NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after two or more treatments because Secura Bio withdrew its evidence submission.
